Genosity Announces Strategic Software Collaboration with PGDx to Support Distribution of PGDx elio™ Tissue Complete to Laboratories
Summary
IGT is a modular platform built with independent but integrated applications, including Gateway, LIMS, Pipeline, Case Analyzer, and Cortex. Genositys Cortex organizes the genomic and clinical data in a knowledgebase to enable population-level analysis and cohort identification to support research collaborations. “Genosity has established a novel software and technical approach that allows laboratories to more effectively implement genetic testing,” said Dr. Marc D. Grodman, MD, co-founder and chief executive officer of Genosity.“PGDx has gained approval for an important assay to help improve the outcomes of cancer patients. The addition of Genosity provides labs an option for a comprehensive solution, built from the ground up for the needs of molecular testing and NGS data.” Genosity is a life science biotechnology company that employs its expertise, novel software solutions and laboratory services for both somatic and germline applications to enable its strategic partners to fully realize the value of precision medicine for both the research and clinical markets. We are committed to improving clinical insight, speed of results, and healthcare economics by delivering a portfolio of regulated tissue-based and liquid biopsy genomic products for health systems worldwide.